Global Leader in Oral Delivery of Therapeutic Proteins
We are a clinical stage company developing oral peptide and protein replacement therapies for significant unmet needs where an oral tablet holds the potential to transform the standard of care.
LATEST NEWS
Press Releases
- September 25, 2024
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
- May 15, 2024
Phase 2 Published in JBMR
- August 20, 2024
Entera Bio Featured in BioTeusdays
- May 3, 2023
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
Events
- August 20, 2024
Entera Bio to Participate in Upcoming Investor and Scientific Conferences – HCW, ASBMR, and Evercore
- September 9, 2022
Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact
Therapeutic Areas
Osteoporosis
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.
SBS & Obesity Programs
We have a collaboration agreement with OPKO to leverage our N-Tab™ technology for the development of an oral GLP-2 for Short Bowel Syndrome and GLP-1/glucagon for obesity.
ABOUT US
Entera is Daring Courageous Fierce
Entera leverages a disruptive and proprietary oral delivery technology platform (N-Tab™) that is designed to stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Our pipeline includes five differentiated, first-in-class oral peptide programs expected to enter the clinic by 2025.
